

FUCHS HENRY J  
Form 4  
June 18, 2018

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
FUCHS HENRY J

2. Issuer Name and Ticker or Trading Symbol  
BIOMARIN PHARMACEUTICAL INC [BMRN]

5. Relationship of Reporting Person(s) to Issuer  
(Check all applicable)  
 Director  10% Owner  
 Officer (give title below)  Other (specify below)  
President, Worldwide R&D

(Last) (First) (Middle)  
C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST.  
(Street)

3. Date of Earliest Transaction (Month/Day/Year)  
06/14/2018

SAN RAFAEL, CA 94901  
(City) (State) (Zip)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
			Code	V	Amount	(A) or (D)	Price		
Common Stock	06/14/2018 <sup>(1)</sup>		M		2,000	A	\$ 21.51	157,167	D
Common Stock	06/14/2018 <sup>(1)</sup>		S		2,000	D	\$ 90	155,167	D
Common Stock	06/14/2018 <sup>(1)</sup>		M		3,775	A	\$ 26.49	158,942	D
Common Stock	06/14/2018 <sup>(1)</sup>		S		3,775	D	\$ 90	155,167	D
	06/14/2018 <sup>(1)</sup>		M		2,669	A	\$ 37.46	157,836	D

Edgar Filing: FUCHS HENRY J - Form 4

Common Stock							
Common Stock	06/14/2018 <sup>(1)</sup>	S	2,669	D	\$ 90	155,167	D
Common Stock	06/14/2018 <sup>(1)</sup>	M	1,875	A	\$ 26.49	157,042	D
Common Stock	06/14/2018 <sup>(1)</sup>	S	1,875	D	\$ 90	155,167	D
Common Stock	06/14/2018 <sup>(1)</sup>	M	20,681	A	\$ 37.46	175,848	D
Common Stock	06/14/2018 <sup>(1)</sup>	S	20,681	D	\$ 90.0041 <u>(2)</u>	155,167	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)
				Code	V (A) (D)	Date Exercisable Expiration Date	Title Amount or Number of Shares
Stock Option (Right to buy Common Stock)	\$ 21.51	06/14/2018 <sup>(1)</sup>		M	2,000	11/12/2010 05/11/2020	Common Stock 2,000
Stock Option (Right to buy Common Stock)	\$ 26.49	06/14/2018 <sup>(1)</sup>		M	3,775	11/12/2011 05/11/2021	Common Stock 3,775
	\$ 37.46	06/14/2018 <sup>(1)</sup>		M	2,669	11/08/2012 05/07/2022	2,669

Stock Option (Right to buy Common Stock)	Price	Grant Date	Exercise	Quantity	Expiration	Common Stock	Quantity
Stock Option (Right to buy Common Stock)	\$ 26.49	06/14/2018 <sup>(1)</sup>	M	1,875	11/12/2011 05/11/2021	Common Stock	1,875
Stock Option (Right to buy Common Stock)	\$ 37.46	06/14/2018 <sup>(1)</sup>	M	20,681	11/08/2012 05/07/2022	Common Stock	20,681

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
FUCHS HENRY J C/O BIOMARIN PHARMACEUTICAL INC. 770 LINDARO ST. SAN RAFAEL, CA 94901			President, Worldwide R&D	

## Signatures

/s/ Eric Fleekop, Attorney-in-Fact 06/18/2018

\_\_Signature of Reporting Person Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Trade made pursuant to a 10b5-1 plan executed on May 30, 2018.  
The price in column 4 is the weighted average price. The price actually received ranged from \$90.00 to \$90.07. The reporting person shall
- (2) provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
- (3) Reflects the number of options outstanding after the transactions from this specific stock option grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.